Join Growin Stock Community!

Cencora, inc.COR.US Overview

US StockHealthcare
(No presentation for COR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

COR AI Insights

COR Overall Performance

COR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

COR Recent Performance

0.26%

Cencora, inc.

0.05%

Avg of Sector

-0.31%

S&P500

COR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

COR Key Information

COR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

COR Profile

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Price of COR

COR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

COR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
8.35
PE Ratio (TTM)
44.62
Forward PE
21.49
PS Ratio (TTM)
0.22
PB Ratio
37.38
Price-to-FCF
19.88
METRIC
VALUE
vs. INDUSTRY
Gross Margin
3.68%
Net Margin
0.50%
Revenue Growth (YoY)
7.45%
Profit Growth (YoY)
19.93%
3-Year Revenue Growth
10.99%
3-Year Profit Growth
12.70%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
8.35
PE Ratio (TTM)
44.62
Forward PE
21.49
PS Ratio (TTM)
0.22
PB Ratio
37.38
Price-to-FCF
19.88
Gross Margin
3.68%
Net Margin
0.50%
Revenue Growth (YoY)
7.45%
Profit Growth (YoY)
19.93%
3-Year Revenue Growth
10.99%
3-Year Profit Growth
12.70%

  • When is COR's latest earnings report released?

    The most recent financial report for Cencora, inc. (COR) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating COR's short-term business performance and financial health. For the latest updates on COR's earnings releases, visit this page regularly.

  • Where does COR fall in the P/E River chart?

    According to historical valuation range analysis, Cencora, inc. (COR)'s current price-to-earnings (P/E) ratio is 39.5, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of COR?

    According to the latest financial report, Cencora, inc. (COR) reported an Operating Profit of 760.45M with an Operating Margin of 0.88% this period, representing a growth of 7.67% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is COR's revenue growth?

    In the latest financial report, Cencora, inc. (COR) announced revenue of 85.93B, with a Year-Over-Year growth rate of 5.45%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does COR have?

    As of the end of the reporting period, Cencora, inc. (COR) had total debt of 7.92B, with a debt ratio of 0.1. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does COR have?

    At the end of the period, Cencora, inc. (COR) held Total Cash and Cash Equivalents of 1.75B, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does COR go with three margins increasing?

    In the latest report, Cencora, inc. (COR) achieved the “three margins increasing” benchmark, with a gross margin of 3.6%%, operating margin of 0.88%%, and net margin of 0.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess COR's profit trajectory and future growth potential.

  • Is COR's EPS continuing to grow?

    According to the past four quarterly reports, Cencora, inc. (COR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.88. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of COR?

    Cencora, inc. (COR)'s Free Cash Flow (FCF) for the period is -2.38B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 15.69% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of COR?

    The latest valuation data shows Cencora, inc. (COR) has a Price-To-Earnings (PE) ratio of 39.5 and a Price/Earnings-To-Growth (PEG) ratio of -0.11. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.